Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SMO | Q99835 | 2/20 | 0.42 |
| ▸ | SLC34A1 | Q06495 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296277 | 0.89 | AR (1.00) | ARCYP1A2SMOSLC34A1NPC1 | |
| SCHEMBL4241463 | 0.83 | AR (0.80) | AR | |
| SCHEMBL4240811 | 0.82 | AR (1.00) | AR | |
| SCHEMBL4233511 | 0.81 | AR (0.70) | ARCYP1A2SMOSLC34A1KDM4E | |
| SCHEMBL4234605 | 0.81 | AR (0.69) | ARCYP1A2SMOSLC34A1KDM4E | |
| SCHEMBL4298378 | 0.79 | AR (0.66) | ARCYP1A2SMOSLC34A1KDM4E | |
| SCHEMBL4236666 | 0.77 | AR (0.64) | ARSLC34A1NPC1RAB9AMEN1 | |
| SCHEMBL4234704 | 0.75 | AR (0.77) | ARNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4303853 | 0.75 | AR (0.60) | ARSMOSLC34A1 | |
| SCHEMBL4239307 | 0.75 | AR (0.60) | ARSMOSLC34A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009119880-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | AR 622/4885CYP1A2 37/4885SMO 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.